News OEM

15 new biomaterials for your immunoassay portfolio expansion

15 new biomaterials for your immunoassay portfolio expansion

December 20, 2022 12:00 PM

Protein Purification

With the goal to better support our partners in their immunoassays, our strategy is to expand and diverse our biomaterials' portfolio. Our target is to increase it by 30 new innovative markers in the next 3 years, and we are excited to share that during 2022 we have already added 15 new markers for 6 different clinical areas:

 

To provide better support for our partners, we have R&D and prototype samples ready for testing, so the performance can be assessed at the initial steps of the development. This way, we reduce risks in later stages of the project, while adapting and optimizing our new biomaterials according to our partners feedback.

Also, you can rely in our biomaterials in catalogue that have been used in several commercial immunoassays.

 

Share Press Release:

LinkedIn twitter facebook
Contact us

Please contact us directly via telephone or with the following form.

Tel. +34 93 860 90 00

DATA PROTECTION POLICY:

Biokit, S.A. and Biokit Research & Development, S.L.U. will process your personal data to respond to your requests for information or support, or to understand your needs and provide you with a better service relying on our legitimate interest to do so. You can find more information about our data privacy practices and how to exercise your rights in our Privacy Policy. You can also contact us at DPO-biokit@werfen.com.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.